STx

The industry’s leading scalable electroporation technology for high yield transient expression of complex proteins, vaccines and biologics.

  • Rapid transfection of 7E4 up to 2E10 cells
  • High efficiency with flexible media strategies deliver significant cost savings
  • Improved yields, at scale, can decrease development timelines
  • Proprietary Flow Electroporation™ Technology
  • Faster production of stable clones
  • cGMP-compliant, ISO-certified, and CE-marked

Want more information on the new STx? Complete the form below and a MaxCyte representative will get back to you promptly.

STx


By clicking the download button, you agree that MaxCyte may collect, use or disclose your personal data which you have provided in this form, for providing marketing material that you have agreed to receive, in accordance with our data protection policy available at MaxCyte Privacy.